OpenURL Connection Search

Select item for more details and to access through your institution.

Survival predictors of 177Lu-Dotatate peptide receptor radionuclide therapy (PRRT) in patients with progressive well-differentiated neuroendocrine tumors (NETS).
Published in:
Journal of Cancer Research & Clinical Oncology, 2022, v. 148, n. 1, p. 225, doi. 10.1007/s00432-021-03672-w
By:
- Swiha, Mina M.;
- Sutherland, Duncan E. K.;
- Sistani, Golmehr;
- Khatami, Alireza;
- Abazid, Rami M.;
- Mujoomdar, Amol;
- Wiseman, Daniele P.;
- Romsa, Jonathan G.;
- Reid, Robert H.;
- Laidley, David T.
Publication type:
Article
Description and assessment of a registration-based approach to include bones for attenuation correction of whole-body PET/MRI.
Published in:
Medical Physics, 2013, v. 40, n. 8, p. 082509, doi. 10.1118/1.4816301
By:
- Marshall, Harry R.;
- Patrick, John;
- Laidley, David;
- Prato, Frank S.;
- Butler, John;
- Théberge, Jean;
- Thompson, R. Terry;
- Stodilka, Robert Z.
Publication type:
Article
Efficacy of 177Lu-Dotatate Induction and Maintenance Therapy of Various Types of Neuroendocrine Tumors: A Phase II Registry Study.
Published in:
Current Oncology, 2021, v. 28, n. 1, p. 115, doi. 10.3390/curroncol28010015
By:
- Sistazni, Golmehr;
- Sutherland, Duncan E. K.;
- Mujoomdar, Amol;
- Wiseman, Daniele P.;
- Khatami, Alireza;
- Tsvetkova, Elena;
- Reid, Robert H.;
- Laidley, David T.
Publication type:
Article
The use of Lutetium-177 PSMA radioligand therapy with high dose rate brachytherapy for locally recurrent prostate cancer after previous definitive radiation therapy: a randomized, single-institution, phase I/II study (ROADSTER).
Published in:
BMC Cancer, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s12885-023-10851-0
By:
- Mendez, Lucas C.;
- Dhar, Aneesh;
- Laidley, David;
- Moussa, Madeleine;
- Gomez, Jose A.;
- Chin, Joseph;
- Lee, T-Y;
- Thiessen, Jonathan D.;
- Hoover, Douglas;
- Surrey, Kathleen;
- Helou, Joelle;
- Velker, Vikram;
- Correa, Rohann J.;
- D'Souza, David;
- Bayani, Jane;
- Bauman, Glenn
Publication type:
Article
Quantitative 68Ga-DOTATATE PET/CT parameters for the prediction of therapy response in patients with progressive metastatic neuroendocrine tumors treated with 177LuDOTATATE .
Published in:
Journal of Nuclear Medicine, 2021, v. 62, n. 12, p. 1, doi. 10.2967/jnumed.120.256727
By:
- Ortega, Claudia;
- Wong, Rebecca K. S.;
- Schaefferkoetter, Josh;
- Veit-Haibach, Patrick;
- Myrehaug, Sten;
- Juergens, Rosalyn;
- Laidley, David;
- Anconina, Reut;
- Liu, Amy;
- Metser, Ur.
Publication type:
Article
Quantitative 68Ga-DOTATATE PET/CT parameters for the prediction of therapy response in patients with progressive metastatic neuroendocrine tumors treated with 177LuDOTATATE.
Published in:
Journal of Nuclear Medicine, 2021, v. 62, n. 11, p. 1, doi. 10.2967/jnumed.120.256727
By:
- Ortega, Claudia;
- Wong, Rebecca K. S.;
- Schaefferkoetter, Josh;
- Veit-Haibach, Patrick;
- Myrehaug, Sten;
- Juergens, Rosalyn;
- Laidley, David;
- Anconina, Reut;
- Liu, Amy;
- Metser, Ur
Publication type:
Article
Quantitative 68Ga-DOTATATE PET/CT parameters for the prediction of therapy response in patients with progressive metastatic neuroendocrine tumors treated with 177LuDOTATATE.
Published in:
Journal of Nuclear Medicine, 2021, v. 62, n. 10, p. 1, doi. 10.2967/jnumed.120.256727
By:
- Ortega, Claudia;
- Wong, Rebecca K. S.;
- Schaefferkoetter, Josh;
- Veit-Haibach, Patrick;
- Myrehaug, Sten;
- Juergens, Rosalyn;
- Laidley, David;
- Anconina, Reut;
- Liu, Amy;
- Metser, Ur
Publication type:
Article
Quantitative 68Ga-DOTATATE PET/CT parameters for the prediction of therapy response in patients with progressive metastatic neuroendocrine tumors treated with 177Lu-DOTATATE.
Published in:
Journal of Nuclear Medicine, 2021, v. 62, n. 8, p. 1, doi. 10.2967/jnumed.120.256727
By:
- Ortega, Claudia;
- Wong, Rebecca K. S.;
- Schaefferkoetter, Josh;
- Veit-Haibach, Patrick;
- Myrehaug, Sten;
- Juergens, Rosalyn;
- Laidley, David;
- Anconina, Reut;
- Liu, Amy;
- Metser, Ur
Publication type:
Article
Quantitative 68Ga-DOTATATE PET/CT parameters for the prediction of therapy response in patients with progressive metastatic neuroendocrine tumors treated with 177Lu-DOTATATE.
Published in:
Journal of Nuclear Medicine, 2021, v. 62, n. 7, p. 1, doi. 10.2967/jnumed.120.256727
By:
- Ortega, Claudia;
- Wong, Rebecca K. S.;
- Schaefferkoetter, Josh;
- Veit-Haibach, Patrick;
- Myrehaug, Sten;
- Juergens, Rosalyn;
- Laidley, David;
- Anconina, Reut;
- Liu, Amy;
- Metser, Ur
Publication type:
Article
Quantitative 68Ga-DOTATATE PET/CT parameters for the prediction of therapy response in patients with progressive metastatic neuroendocrine tumors treated with 177Lu-DOTATATE.
Published in:
Journal of Nuclear Medicine, 2021, v. 62, n. 6, p. 23, doi. 10.2967/jnumed.120.256727
By:
- Ortega, Claudia;
- Wong, Rebecca K. S.;
- Schaefferkoetter, Josh;
- Veit-Haibach, Patrick;
- Myrehaug, Sten;
- Juergens, Rosalyn;
- Laidley, David;
- Anconina, Reut;
- Liu, Amy;
- Metser, Ur
Publication type:
Article
Quantitative 68Ga-DOTATATE PET/CT parameters for the prediction of therapy response in patients with progressive metastatic neuroendocrine tumors treated with 177Lu-DOTATATE.
Published in:
Journal of Nuclear Medicine, 2021, v. 62, n. 5, p. 1, doi. 10.2967/jnumed.120.256727
By:
- Ortega, Claudia;
- Wong, Rebecca K. S.;
- Schaefferkoetter, Josh;
- Veit-Haibach, Patrick;
- Myrehaug, Sten;
- Juergens, Rosalyn;
- Laidley, David;
- Anconina, Reut;
- Liu, Amy;
- Metser, Ur
Publication type:
Article
Quantitative 68Ga-DOTATATE PET/CT parameters for the prediction of therapy response in patients with progressive metastatic neuroendocrine tumors treated with 177Lu-DOTATATE.
Published in:
Journal of Nuclear Medicine, 2021, v. 62, n. 3, p. 1, doi. 10.2967/jnumed.120.256727
By:
- Ortega, Claudia;
- Wong, Rebecca K. S.;
- Schaefferkoetter, Josh;
- Veit-Haibach, Patrick;
- Myrehaug, Sten;
- Juergens, Rosalyn;
- Laidley, David;
- Anconina, Reut;
- Liu, Amy;
- Metser, Ur
Publication type:
Article
Microscopic Positive Tumor Margin Increases Risk for Disease Persistence but Not Recurrence in Patients with Stage T1-T2 Differentiated Thyroid Cancer.
Published in:
Journal of Thyroid Research, 2020, p. 1, doi. 10.1155/2020/5287607
By:
- Kamel Hasan, Olfat;
- De Brabandere, Sarah;
- Rachinsky, Irina;
- Laidley, David;
- MacNeil, Danielle;
- Van Uum, Stan
Publication type:
Article
Imaging Biomarkers in Prostate Stereotactic Body Radiotherapy: A Review and Clinical Trial Protocol.
Published in:
Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.863848
By:
- Liu, Wei;
- Loblaw, Andrew;
- Laidley, David;
- Fakir, Hatim;
- Mendez, Lucas;
- Davidson, Melanie;
- Kassam, Zahra;
- Lee, Ting-Yim;
- Ward, Aaron;
- Thiessen, Jonathan;
- Bayani, Jane;
- Conyngham, John;
- Bailey, Laura;
- Andrews, Joseph D.;
- Bauman, Glenn
Publication type:
Article
Case series--18F-DCFPyL-positron emission tomography/computed tomography (PET/CT) time of imaging.
Published in:
Canadian Urological Association Journal, 2021, v. 15, n. 7, p. E376, doi. 10.5489/cuaj.6984
By:
- Sistani, Golmehr;
- Metser, Ur;
- Bauman, Glenn S.;
- Laidley, David T.;
- Pautler, Stephen E.;
- Zukotynski, Katherine A.
Publication type:
Article
177 Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: A Review of the Evidence and Implications for Canadian Clinical Practice.
Published in:
Current Oncology, 2024, v. 31, n. 3, p. 1400, doi. 10.3390/curroncol31030106
By:
- Chi, Kim N.;
- Yip, Steven M.;
- Bauman, Glenn;
- Probst, Stephan;
- Emmenegger, Urban;
- Kollmannsberger, Christian K.;
- Martineau, Patrick;
- Niazi, Tamim;
- Pouliot, Frédéric;
- Rendon, Ricardo;
- Hotte, Sebastien J.;
- Laidley, David T.;
- Saad, Fred
Publication type:
Article

Found: 16

Survival predictors of <sup>177</sup>Lu-Dotatate peptide receptor radionuclide therapy (PRRT) in patients with progressive well-differentiated neuroendocrine tumors (NETS).

Description and assessment of a registration-based approach to include bones for attenuation correction of whole-body PET/MRI.

Efficacy of <sup>177</sup>Lu-Dotatate Induction and Maintenance Therapy of Various Types of Neuroendocrine Tumors: A Phase II Registry Study.

The use of Lutetium-177 PSMA radioligand therapy with high dose rate brachytherapy for locally recurrent prostate cancer after previous definitive radiation therapy: a randomized, single-institution, phase I/II study (ROADSTER).

Quantitative <sup>68</sup>Ga-DOTATATE PET/CT parameters for the prediction of therapy response in patients with progressive metastatic neuroendocrine tumors treated with <sup>177</sup>LuDOTATATE .

Quantitative <sup>68</sup>Ga-DOTATATE PET/CT parameters for the prediction of therapy response in patients with progressive metastatic neuroendocrine tumors treated with <sup>177</sup>LuDOTATATE.

Quantitative <sup>68</sup>Ga-DOTATATE PET/CT parameters for the prediction of therapy response in patients with progressive metastatic neuroendocrine tumors treated with <sup>177</sup>LuDOTATATE.

Quantitative <sup>68</sup>Ga-DOTATATE PET/CT parameters for the prediction of therapy response in patients with progressive metastatic neuroendocrine tumors treated with <sup>177</sup>Lu-DOTATATE.

Quantitative <sup>68</sup>Ga-DOTATATE PET/CT parameters for the prediction of therapy response in patients with progressive metastatic neuroendocrine tumors treated with <sup>177</sup>Lu-DOTATATE.

Quantitative <sup>68</sup>Ga-DOTATATE PET/CT parameters for the prediction of therapy response in patients with progressive metastatic neuroendocrine tumors treated with <sup>177</sup>Lu-DOTATATE.

Quantitative <sup>68</sup>Ga-DOTATATE PET/CT parameters for the prediction of therapy response in patients with progressive metastatic neuroendocrine tumors treated with <sup>177</sup>Lu-DOTATATE.

Quantitative <sup>68</sup>Ga-DOTATATE PET/CT parameters for the prediction of therapy response in patients with progressive metastatic neuroendocrine tumors treated with <sup>177</sup>Lu-DOTATATE.

Microscopic Positive Tumor Margin Increases Risk for Disease Persistence but Not Recurrence in Patients with Stage T1-T2 Differentiated Thyroid Cancer.

Imaging Biomarkers in Prostate Stereotactic Body Radiotherapy: A Review and Clinical Trial Protocol.

Case series--<sup>18</sup>F-DCFPyL-positron emission tomography/computed tomography (PET/CT) time of imaging.

177 Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: A Review of the Evidence and Implications for Canadian Clinical Practice.